Skip to main
TOI

TOI Stock Forecast & Price Target

TOI Analyst Ratings

Based on 3 analyst ratings
Strong Buy
Strong Buy 100%
Buy 0%
Hold 0%
Sell 0%
Strong Sell 0%

Bulls say

Oncology Institute is well-positioned for success in the healthcare industry due to their optimized workflows and potential for growth in their Specialty Pharmacy segment. Their strong cost management and expansion plans make them a promising investment, but competition and debt may pose risks. With positive results expected from current initiatives and a rapidly growing oncology market, their stock has the potential to rise above the current price of $9.

Bears say

Oncology Institute is predicted to outperform FY26 guidance and achieve high single-digit EBITDA margins by 2028 through the launch of a provider portal and increasing its capitated contracts. However, the lack of contribution from net new wins in FY26 may hinder its potential for higher dispensary revenue and there is a risk of increased competition from other healthcare providers. The current valuation at EV/0.6x 2027 estimated revenue suggests an undervaluation for TOI compared to its peers, but there are risks associated with medical costs and potential limitations for future growth.

TOI has been analyzed by 3 analysts, with a consensus rating of Strong Buy. 100% of analysts recommend a Strong Buy, 0% recommend Buy, 0% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of The Oncology Institute and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About The Oncology Institute (TOI) Forecast

Analysts have given TOI a Strong Buy based on their latest research and market trends.

According to 3 analysts, TOI has a Strong Buy consensus rating as of Jun 26, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $7.67, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $7.67, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

The Oncology Institute (TOI)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.